P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000970592.64148.2c |
| _version_ | 1797281651804340224 |
|---|---|
| author | Maria-Victoria Mateos Katja Weisel Tom Martin Jesus Berdeja Andrzej Jakubowiak Keith Stewart Sundar Jagannath Yi Lin Joris Diels Francesca Ghilotti Pushpike Thilakarathne Nolen Perualila Jedelyn Cabrieto Nichola Erler-Yates Carolyn C Jackson Jordan Schecter Vadim Strulev Imene Haddad Octavio Costa Filho Lida Pacaud Hermann Einsele Philippe Moreau |
| author_facet | Maria-Victoria Mateos Katja Weisel Tom Martin Jesus Berdeja Andrzej Jakubowiak Keith Stewart Sundar Jagannath Yi Lin Joris Diels Francesca Ghilotti Pushpike Thilakarathne Nolen Perualila Jedelyn Cabrieto Nichola Erler-Yates Carolyn C Jackson Jordan Schecter Vadim Strulev Imene Haddad Octavio Costa Filho Lida Pacaud Hermann Einsele Philippe Moreau |
| author_sort | Maria-Victoria Mateos |
| collection | DOAJ |
| first_indexed | 2024-03-07T17:00:30Z |
| format | Article |
| id | doaj.art-ed34d4fab23c4c53b356ddc52817f825 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:00:30Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-ed34d4fab23c4c53b356ddc52817f8252024-03-03T03:25:31ZengWileyHemaSphere2572-92412023-08-017e641482c10.1097/01.HS9.0000970592.64148.2c202308003-00822P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDYMaria-Victoria Mateos0Katja Weisel1Tom Martin2Jesus Berdeja3Andrzej Jakubowiak4Keith Stewart5Sundar Jagannath6Yi Lin7Joris Diels8Francesca Ghilotti9Pushpike Thilakarathne10Nolen Perualila11Jedelyn Cabrieto12Nichola Erler-Yates13Carolyn C Jackson14Jordan Schecter15Vadim Strulev16Imene Haddad17Octavio Costa Filho18Lida Pacaud19Hermann Einsele20Philippe Moreau211 University Hospital of Salamanca/IBSAL/CIC, Salamanca, Spain2 University Medical Center Hamburg-Eppendorf, Hamburg, Germany3 UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, United States4 Sarah Cannon Research Institute, Nashville, United States5 University of Chicago, Chicago, United States6 University Health Network and the Princess Margaret Cancer Centre, Toronto, Canada7 Mount Sinai Medical Center, New York, United States8 Mayo Clinic, Rochester, United States9 Janssen Pharmaceutica NV, Beerse, Belgium10 Janssen-Cilag SpA, Cologno Monzese, Italy9 Janssen Pharmaceutica NV, Beerse, Belgium9 Janssen Pharmaceutica NV, Beerse, Belgium9 Janssen Pharmaceutica NV, Beerse, Belgium11 Janssen-Cilag GmbH, Neuss, Germany12 Janssen R&D, Raritan, United States12 Janssen R&D, Raritan, United States13 Janssen Pharmaceutica NV, EMEA Medical Affairs, Beerse, Belgium14 Janssen-Cilag, Issy-les-Moulineaux, France15 Legend Biotech USA, Piscataway, United States15 Legend Biotech USA, Piscataway, United States16 Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany17 University Hospital Hotel-Dieu, Clinical Hematology, Nantes, Francehttp://journals.lww.com/10.1097/01.HS9.0000970592.64148.2c |
| spellingShingle | Maria-Victoria Mateos Katja Weisel Tom Martin Jesus Berdeja Andrzej Jakubowiak Keith Stewart Sundar Jagannath Yi Lin Joris Diels Francesca Ghilotti Pushpike Thilakarathne Nolen Perualila Jedelyn Cabrieto Nichola Erler-Yates Carolyn C Jackson Jordan Schecter Vadim Strulev Imene Haddad Octavio Costa Filho Lida Pacaud Hermann Einsele Philippe Moreau P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY HemaSphere |
| title | P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY |
| title_full | P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY |
| title_fullStr | P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY |
| title_full_unstemmed | P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY |
| title_short | P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY |
| title_sort | p922 adjusted comparisons of ciltacabtagene autoleucel with therapies from real world clinical practice two year follow up analyses from cartitude 1 and the prospective locommotion study |
| url | http://journals.lww.com/10.1097/01.HS9.0000970592.64148.2c |
| work_keys_str_mv | AT mariavictoriamateos p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT katjaweisel p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT tommartin p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT jesusberdeja p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT andrzejjakubowiak p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT keithstewart p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT sundarjagannath p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT yilin p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT jorisdiels p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT francescaghilotti p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT pushpikethilakarathne p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT nolenperualila p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT jedelyncabrieto p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT nicholaerleryates p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT carolyncjackson p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT jordanschecter p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT vadimstrulev p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT imenehaddad p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT octaviocostafilho p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT lidapacaud p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT hermanneinsele p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy AT philippemoreau p922adjustedcomparisonsofciltacabtageneautoleucelwiththerapiesfromrealworldclinicalpracticetwoyearfollowupanalysesfromcartitude1andtheprospectivelocommotionstudy |